anti human cd39 a1 160gd (fluidigm)
fluidigm is a verified supplier 
fluidigm manufactures this product 
93
Structured Review
fluidigm
anti human cd39 a1 160gd
Anti Human Cd39 A1 160gd, supplied by fluidigm, used in various techniques. Bioz Stars score: 93/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd39/Anti-Human+CD39+(A1)-160Gd/pmc13006393-86-0-5
Average 93 stars, based on 7 article reviews
Anti Human Cd39 A1 160gd, supplied by fluidigm, used in various techniques. Bioz Stars score: 93/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd39/Anti-Human+CD39+(A1)-160Gd/pmc13006393-86-0-5
Average 93 stars, based on 7 article reviews
anti human cd39 a1 160gd - by Bioz Stars,
2026-11
93/100 stars
Images
1) Product Images from "Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial"
Article Title: Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial
Journal: Cell Reports Medicine
doi: 10.1016/j.xcrm.2026.102638
Figure Legend Snippet: Phenotypic modulation of T cells and enhanced priming by anti-CTLA4-NF (A) PaCMAP plot of NeoRED-P patient tumor-infiltrating CD8 T cells by CyTOF. Clusters were derived from FlowSOM. (B) Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment group. (C) Expression of CD39 and 4-1BB by geometric MI on CD8 T cells as represented by color mapping on PaCMAP plot. (D) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. Untreated, n = 7; ADT, n = 8; ADT + anti-CTLA4-NF, n = 8. Single patient with MSI hi status called out in plot. For this and all violin plots to follow, solid lines denote group medians, while dashed lines denote quartiles. (E) PaCMAP plot of NeoRED-P patient tumor-infiltrating CD4 + FoxP3 - Tconv cells by CyTOF. Clusters were derived from FlowSOM. (F) Pseudocolor density plots of CD4 Tconv cells in PaCMAP space stratified by treatment group. (G) Expression of CD39 and 4-1BB by geometric MI on CD4 Tconv as represented by color mapping on PaCMAP plot. (H) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD4 Tconv cells as a percentage of all CD8 T cells stratified by treatment group. Untreated, n = 7; ADT, n = 8; ADT + anti-CTLA4-NF, n = 8. Single patient with MSI hi status called out in plot. (I) PaCMAP plot of MycCaP-infiltrating CD8 T cells by 45-parameter flow cytometry in response to ADT, ADT + anti-CTLA4 (ND), or ADT + anti-CTLA4 (D). Clusters were derived from FlowSOM. (J) Pseudocolor density plots of CD8 T cells in PaCMAP space stratified by treatment group. (K) Expression of CD39 and 4-1BB by geometric MFI on CD8 T cells as represented by color mapping on PaCMAP plot. (L) Violin plot representing frequency of manually gated CD39 + 4-1BB + CD8 T cells as a percentage of all CD8 T cells stratified by treatment group. (M) Biaxial plots representing expression of CD44 and Ki67 on CD8 T cells in tumor-draining lymph nodes of mice shown in (I–L). (N) Biaxial plots representing expression of CD44 and Ki67 on CD4 + FoxP3 − Tconv cells in tumor-draining lymph nodes of mice shown in (L–O). (O) Violin plots representing frequencies of CD44 + Ki67 + CD8 and CD4 Tconv cells as a percentage of parent populations stratified by treatment group. Two-tailed Welch’s t test was used to assess statistical significance. All murine data shown are n = 7 per group and representative of two independent experiments each for survival and immune profiling studies.
Techniques Used: Derivative Assay, Expressing, Flow Cytometry, Two Tailed Test
Related Articles
other:Article Title: Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial Article Snippet: Article Title: Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells Article Snippet: Recombinase Polymerase Amplification:Article Title: Spatial dynamics of CD39 + CD8 + exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer Article Snippet: The following primary antibodies and detection systems were used for critical IHC assays: PD-L1 antibody (28-8) IHC antigen retrieval and detection panel (Abcam, Clone 28-8, Cat No. ab236676, 1:50), Anti-PD-1 (Abcam, Clone NAT105, Cat No. ab52587, 1:50), AntiCD39 (Abcam, Clone ERP20627, Cat No. ab223842, 1:500), Anti-CD8 (Leica Biosystems, Clone 4B11, Cat No. PA0183, Prediluted), Goat anti-mouse IgG2b CF Dye 647 (Biotium, Polyclonal, Cat No. 20272-1, 1:800), Goat anti-mouse IgG1 CF Dye 488 (Biotium, Polyclonal, Cat No. 20246-1, 1:800), Goat anti-rabbit IgG CF Dye 568 (Biotium, Polyclonal, Cat No. 20103-1, 1:800), EnVision+ Dual Link System-HRP (DAB+) (Agilent Technologies, Cat No. K406311, Prediluted), Anti-CD3 (Agilent Technologies, Clone F7.2.38, Cat No. M7254, 1:20), Anti-CD20cy (Agilent Technologies, Clone L26, Cat No. IS604, Prediluted), and Anti-PNA (Novus, Clone MECA79R, Cat No. NBP2-78792, 1:100). .. The following primary antibodies were used for MC: CD45-106Cd (Fluidigm, Clone HI30, Cat No. 3106001B, 1:100), CD45-110Cd (Fluidigm, Clone HI30, Cat No. 3110001B, 1:100), CD45-111Cd (Fluidigm, Clone HI30, Cat No. 3111001B, 1:100), CD45-112Cd (Fluidigm, Clone HI30, Cat No. 3112001B, 1:100), CD45-113Cd (Fluidigm, Clone HI30, Cat No. 3113001B, 1:100), CD45-114Cd (Fluidigm, Clone HI30, Cat No. 3114001B, 1:100), CCR6-141Pr (Fluidigm, Clone 11A9, Cat No. 3141014A, 1:100), CD45RA-143Nd (Fluidigm, Clone HI100, Cat No. 3143006B, 1:100), CD4-145Nd (Fluidigm, Clone RPA-T4, Cat No. 3145001B, 1:100), CD8-146Nd (Fluidigm, Clone RPA-T8, Cat No. 3146001B, 1:100), Ki67-147Sm (BioLegend, Clone Ki67, Cat No. 350523, 1:100), CD25-149Sm (Fluidigm, Clone 2A3, Cat No. 3149010B, 1:100), OX-40-150Nd (Fluidigm, Clone ACT35, Cat No. 3150023B, 1:100), CD28-152Sm (BioLegend, Clone CD28.2, Cat No. 302937, 1:100), TIM-3-153Eu (Fluidigm, Clone F38-2E2, Cat No. 3153008B, 1:100), CD3-154Sm (Fluidigm, Clone UCHT1, Cat No. 3154003B, 1:100), TOX-155Gd (Miltenyi Biotec, Clone REA473, Cat No. 130-126-455, 1:100), CXCR3-156Gd (Fluidigm, Clone G025H7, Cat No. 3156004B, 1:100), CD27-158Gd (Fluidigm, Clone L128, Cat No. 3158010B, 1:100), FoxP3-159Tb (Fluidigm, Clone 259D/C7, Cat No. 3159028A, 1:100), |